Abstract:
Thymosin .alpha..sub.1, was chemically synthesized by the fragment condensation of the protected amino terminal tetradecapeptide with the protected carboxyl terminal tetradecapeptide and by solid phase peptide synthesis. Thymosin .alpha..sub.1 is active as an agent which affects regulation, differentiation and function of thymus dependent lymphocytes (T cells).
Abstract:
Thymosin .alpha..sub.1, was chemically synthesized by the fragment condensation of the protected amino terminal tetradecapeptide with the protected carboxyl terminal tetradecapeptide. Similarly prepared was the analog [Asn.sup.2 ]-thymosin .alpha..sub.1 utilizing the appropriately modified protected amino terminal tetradecapeptide. Both products are active as agents which affect regulation, differentiation and function of thymus dependent lymphocytes (T cells).
Abstract:
The present invention relates to peptides having strong LH-RH/FSH-RH activity, wherein Gly in the 6-position is replaced by different substituted amino acids and in the 10-position there is glycinamide or glycine in the 10-position is replaced by a NH-alkyl group with 1-3 carbon atoms or a NH-cyclopropyl group. The invention relates as well to a process for manufacturing said peptides, and to pharmaceutical preparations containing said peptides.
Abstract:
Synthetic hypocalcaemic dotriacontapeptide of the formulaH-Cys-Ser-Asn-Leu-Ser--Thr-Cys-Val-Leu-Ser-Ala-Tyr-Try-Arg-Asn-Leu-Asn-Asn-Phe-His-Arg-Phe-Ser-Gly-Met-Gly-Phe-Gly-Pro-Glu-Thr-Pro-OH Iand analogues and derivatives, salts and complexes thereof and process for their manufacture.
Abstract:
A synthetic decapeptide, L-pglutamyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycinamide which has the hormonal activities of the luteinizing hormone releasing hormone (LRH) of the hypothalamus gland of mammals is produced by utilizing as the key starting materials, the amino acids, glutamic acid or pyroglutamic acid, histidine, tryptophan, serine, tyrosine, glycine, leucine, arginine, and proline. Synthesis of the decapeptide is accomplished by coupling, in appropriate combinations of appropriate protected forms of the amino acids, and finally deprotecting to yield the amide, L-pglutamyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycinamide.
Abstract:
The new hypocalcaemic peptides of the formula
wherein X represents the L-methionine, L-valine, L-norvaline, Lleucine, L-isoleucine, L-norleucine or L- Alpha -aminobutyric acid radical, above all the L-methionine or L-valine radical, and wherein L-alanine26 is replaced by L-asparagine and/or Lisoleucine27 is replaced by L-threonine, and wherein optionally one or more of the aminoacids in positions 11, 12, 16, 19, 22 and 24 is or are replaced by another aminoacid, namely L-threonine11 by L-lysine, L-tyrosine12 by L-leucine, L-phenylalanine16 by Lleucine, L-phenylalanine19 by L-leucine, L-phenylalanine22 by Ltyrosine and L-glutamine24 by L-arginine.
IN WHICH R IS HYDROGEN, METHYL, ETHYL, P-NITROBENZYL, OR BENZYL; R2 IS T-BUTYL OR BANZYL; AND, WHEN R2 IS T-BUTYL, R4 IS H-, CBZ-, OR (ADOC)2-L-HIS-; AND, WHEN R2 IS BENZYL, R4 IS H-, CHZ-, BOC-, AOC-, ADOC-, OR (ADOC)2-L-HIS-.
Abstract:
THIS INVENTION RELATES TO INTERMEDIATES AND THEIR SALTS USEFUL IN THE PREPARATION OF THE GASTROINTESTINAL HORMONE, SECRETIN. THE INTERMEDIATES OF THIS INVENTION COMPRISE PARTIAL SEQUENCES OF AMINO ACIDS, WHICH, WHEN COMBINED, FORM THE SECRETIN MOLECULE. THE NOVEL PROTECTIVE PEPTIDES CORRESPONDING TO THESE PARTIAL SEQUENCES ARE: (1) PROTECTED L-HISTIDYL-L-SERYL-L-ASPARTGLYGLYCINE; (AMINO ACIDS 1 TO 4); (2) PROTECTED L-THREONYL-L-PHENYLALANYL-L-THREONYL-L SERINE HYDRAZIDE; (AMINO ACIDS 5 TO 8); (3) PROTECTED L-GLUTAMYL-L-LEUCYL-L-SERYL-L-ARGINYL-LLEUCINE HYDRAZIDE; (AMINO ACIDS 9 TO 13); AND (4) PROTECTED L-ARGINYL-L-ASPARTYL-L-SERYL-L-ALANYL-LARGINYL-L-LEUCYL-L-GLUTAMINYL-L -ARGINYL-L-LEUCY-LGLUTAMINYLGLYCYL-L-LEUCYL-L-VALINAMIDE; (AMINO ACIDS 14 TO 27).
Abstract:
THE INVENTION DESCRIBES A NEW PENTACOSAPEPTIDE OF THE FORMULA. D-SERYL-L-TYROSYL-L-SERYL-L-NORLEUCYL-L-GLUTAMYL-L-HISTIDYL-L-PHENYLALANYL-L-ARGINGYL-L-TRYPTOPHANYLGLYCYL-L-LYSYL-L-PROLYL-L-VALYL-GLYCYL-L-LYSYL-L -LYSYL-LARGINYL-L-ARGINYL-L-PROLYL-L-VALYL-L-HYSYL-L-VALYL-LTYROSYL-L-PROLYL-L-VALINAMIDE, ITS THERAPEUTICALLY ACTIVE ACID ADDITION SALTS AND HEAVY METAL COMPLEXES. THE POLYPEPTIDE OF THE INVENTION, ALSO NAMED D-SER1-NIE4-VALNH2**25A1**25-ACTH, IS PHARMACEUTICALLY USEFUL BECAUSE OF ITS HIGH ADRENOCORITCOTROPIC EFFECT.
Abstract:
The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: The compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions.